Skip to main content

CORRECTION article

Front. Pharmacol., 31 January 2022
Sec. Ethnopharmacology
Volume 12 - 2021 | https://doi.org/10.3389/fphar.2021.814501

Corrigendum: Tengdan Capsule Prevents Hypertensive Kidney Damage in SHR by Inhibiting Periostin-Mediated Renal Fibrosis

This article is a correction to:

  1. Tengdan Capsule Prevents Hypertensive Kidney Damage in SHR by Inhibiting Periostin-Mediated Renal Fibrosis

    1. Read original article
Xiaoli Du,,Xiaoli Du1,2,3Qianqian Tao,Qianqian Tao1,3Hongxia Du,Hongxia Du1,3Zhenbang ZhaoZhenbang Zhao2Yu Dong,Yu Dong1,2Shuang He,Shuang He1,3Rui Shao,Rui Shao1,3Yule Wang,Yule Wang1,3Wenrun Han,Wenrun Han1,3Xintong Wang,Xintong Wang1,3Yan Zhu, Yan Zhu1,3*
  • 1Institute of Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China
  • 2Department of Pharmacy, Inner Mongolia Medical College, Hohhot, China
  • 3Tianjin International Joint Academy of Biomedicine, Tianjin, China

A corrigendum on
Tengdan Capsule Prevents Hypertensive Kidney Damage in SHR by Inhibiting Periostin-Mediated Renal Fibrosis

by Du, X., Tao, Q., Du, H., Zhao, Z., Dong, Y., He, S., Shao, R., Wang, Y., Han, W., Wang, X., and Zhu, Y. Front. Pharmacol. 12:638298. doi: 10.3389/fphar.2021.638298

In the original article, there was a mistake in Figure 2 as published. The Figure 1 was accidentally duplicated in the proof stage. The correct Figure 2 appears below.

FIGURE 2
www.frontiersin.org

FIGURE 2. Effects of TDC on noninvasive blood pressure in SHR (A–C) Representative data plots of SBP, DBP, and MBP measurements, respectively, over 4 weeks using the noninvasive tail-cuff method in conscious rats (D) Bar graph comparison of the MBP in the four rat groups at day 28. Data are expressed as mean ± SD, n = 5–6. ****p < 0.0001 vs. WKY rats; ##p < 0.01, ###p < 0.001 vs. SHR.>

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: hypertension-induced kidney damage, periostin, TGFÎ2/SMAD signaling pathway, inflammatory response, human kidney HEK293 cells

Citation: Du X, Tao Q, Du H, Zhao Z, Dong Y, He S, Shao R, Wang Y, Han W, Wang X and Zhu Y (2022) Corrigendum: Tengdan Capsule Prevents Hypertensive Kidney Damage in SHR by Inhibiting Periostin-Mediated Renal Fibrosis. Front. Pharmacol. 12:814501. doi: 10.3389/fphar.2021.814501

Received: 13 November 2021; Accepted: 24 November 2021;
Published: 31 January 2022.

Edited and reviewed by:

Shuai Ji, Xuzhou Medical University, China

Copyright © 2022 Du, Tao, Du, Zhao, Dong, He, Shao, Wang, Han, Wang and Zhu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Yan Zhu, yanzhu.harvard@icloud.com

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.